What is Leqvio and How Does it Work?
Leqvio (inclisiran) is a medication used to lower low-density lipoprotein cholesterol (LDL-C) in adults. It is administered by a healthcare professional via subcutaneous injection [1]. Leqvio works by targeting and degrading the messenger RNA (mRNA) for proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that promotes the degradation of LDL receptors in the liver. By reducing PCSK9 levels, Leqvio increases the number of LDL receptors available to remove LDL-C from the bloodstream [1].
How is Leqvio Covered by Medicare?
Medicare Part B generally covers Leqvio when it is administered in a doctor's office or hospital outpatient setting [2]. Patients with Medicare Part B may be responsible for a coinsurance payment, typically 20% of the Medicare-approved amount for the drug after meeting their deductible [2]. The exact out-of-pocket cost can vary depending on the specific Medicare plan and the location of administration [2].
What Factors Influence Leqvio's Medicare Reimbursement?
The reimbursement of Leqvio by Medicare Part B is contingent on it being medically necessary and administered by a qualified healthcare provider. It is typically covered as an outpatient drug administered in a clinical setting [2]. The Centers for Medicare & Medicaid Services (CMS) determines coverage policies and payment rates for such medications [2].
When Does Leqvio's Patent Exclusivity End?
Information regarding the patent exclusivity for Leqvio is available through resources like DrugPatentWatch.com. The duration of patent protection and potential market exclusivity are critical factors in determining when generic or biosimilar versions of a drug might become available [3]. Understanding these timelines is essential for assessing future market dynamics and potential cost changes.
What Are the Potential Out-of-Pocket Costs for Patients?
For Medicare beneficiaries, out-of-pocket costs for Leqvio will depend on several factors, including whether the Part B deductible has been met, the coinsurance rate (typically 20%), and any supplemental insurance coverage they may have [2]. Patients are advised to check with their specific Medicare plan provider and their healthcare provider's office for the most accurate cost estimates.
How Does Leqvio Compare to Other Cholesterol-Lowering Medications?
Leqvio represents a novel approach to LDL-C reduction due to its infrequent dosing schedule, with maintenance doses given every six months after initial doses [1]. Unlike statins, which are taken daily, Leqvio is an RNA interference (RNAi) therapy. Other injectable medications for high cholesterol, such as PCSK9 inhibitors like evolocumab and alirocumab, are also available and work by inhibiting the PCSK9 protein, but they require injections every two to four weeks [1].
Are There Patient Assistance Programs for Leqvio?
Manufacturers often provide patient assistance programs for high-cost medications. Information on any available programs for Leqvio, which could help reduce out-of-pocket expenses for eligible patients, can typically be found on the drug's official website or through their healthcare provider.
What is the Typical Dosing Schedule for Leqvio?
Leqvio is administered as an initial dose, a second dose at 3 months, and then a maintenance dose every 6 months thereafter [1].
Sources:
1. Leqvio (inclisiran) Prescribing Information
2. Medicare Coverage of Injectable Drugs
3. DrugPatentWatch.com